drugset / Trial / NCT05172856
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2023-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI321 | Unknown | — | Intravenous |
Indications
No indication recorded.